physician-scientist, author, editor
The SOLIDARITY randomized trial of 4 repurposed drugs in 11, 266 hospitalized patients with #COVID19: HCQ, Remdesivir, Interferon, Lopinavir (each vs placebo)
All without effect on survival or secondary endpoints
Disappointing results, and perhaps also a good reminder that we shouldn't expect all items in the development pipeline (including vaccines) to fix all our pandemic problems right away. This is why we do clinical trials. twitter.com/EricTopol/stat…
Mathematician/epidemiologist at @LSHTM. @WellcomeTrust fellow and @TEDFellow. Author of The Rules of Contagion. Views own.
"Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay." medrxiv.org/content/10.110…
Not the result anyone hoped for. But so important to have robust, definitive data from large randomised trials. Huge credit to everyone involved in @WHO coordinated Solidarity Trial medrxiv.org/content/10.110…
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint medrxiv.org/content/10.110…pic.twitter.com/daOAMVW62u
What do you think?
If you would like to dissect and discuss the study in depth with ID physicians, pharmacists, trialists, and a range of trainees, I invite you to join our Twitter-based journal club, #IDJClub, on October 26 at 9 ET. Everyone welcome! twitter.com/idjclub/status…
Clinician Scientist @UofT_DoM | General internist @SinaiHealth | Affiliated Faculty @PORTAL_Research | v. amateur golfer/gardener/goalie
.#SOLIDARITY results are out as preprint in @medrxivpreprint ! N=11,000+ hospitalized with #COVID, randomized to remdesivir, hydroxychloroquine, lopinavir-ritonavir, interferon B1a vs standard of care. 1/4
Bottom line: in general it doesn’t seem like any of these agents work and some may harm (e.g., hydroxychloroquine). Yup, this is disappointing. But there are some glimmers of hope of subgroups that MIGHT benefit from remdesivir 2/4
What is next? The #SOLIDARITY trial continues. New arms will be added (e.g., monoclonal antibodies) and as noted the Remdesivir arm will also continue. And this is the only way we will know if things work. Through large, multicentre, international, randomized trials. 4/4
Asst. Prof @UofA_ID. I tweet about #emergingfungalinfections, #TxID, #IDTwitter, #covid19. Education Co-Chair (#SoMe) @msg_erc; cofounder @idjclub (He/Him)
Solidarity preliminary report now published (as pre-print)
Clearly zero overall 28 d mortality benefit to remdesivir
“This absolutely excludes the suggestion that Remdesivir can prevent a substantial fraction of all deaths”
With regards to subgroup analysis, authors caution:
“The statistical uncertainties are much greater if attention is restricted to particular subgroups or time periods... neither subtotal should be considered in isolation from the other subtotal, or from the CI for the total” pic.twitter.com/m6QDHxL9SH
Comes to show that nucleoside analogues have to be given extremely early during infection if one could even hope for an effect. It's too late when people are hospitalized.
For now, they're useful lab tools, but that's about it twitter.com/GermHunterMD/s…
“Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.” twitter.com/MackayIM/statu…
Epidemiologist. Blogger. Writer (Guardian, Observer etc). PhDing at @UoW Host of @senscipod Email firstname.lastname@example.org he/him
WHO results from the massive SOLIDARITY trial are out
The findings are pretty bleak. No discernible benefit for hydroxychloroquine, lopinavir/ritonavir, remdesivir, or interferon on any endpoint (death, ventilation, discharge)
Professor of Infectious Diseases, University of Cape Town. Co-chair South African Antibiotic Stewardship Programme. Views are my own
#Dexamethasone & equivalent steroids. remain the only therapeutic to reduce mortality from #COVID19 as @WHO SOLIDARITY trial results indicate no effect of #Remdesivir and interferon on reducing death rates medrxiv.org/content/10.110…
Infectious Diseases Physician and Microbiologist. Professor Medical School. Australian National University
Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. medrxiv.org/content/10.110…
Dr Gaetan Burgio, MD, PhD.
Fri Oct 16
Who said the #hydroxychloroquine treatment for #COVID19 is innocuous and no risk? Here is the results from the SOLIDARITY trial (@WHO) showing the probability effect on cardiac death at 14 and 28 days post treatment
Antibiotic Steward🆔 Bassam Ghanem
Thu Oct 15
405 hospitals, 30 countries, n=11k
Interim results indicate Rremdesivir,HCQ,lopinavir/ritonavir&interferon regimens appeared to have little or no effect on 28-day mortality /the in-hospital course of #COVID19
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results | Unfortunately no effects of Remdesivir, hydroxychloroquine, Kaletra or interferon @doctorsoumya @WHO medrxiv.org/content/10.110…
Infectious Diseases physician and scientist, with thoughts on Infectious Diseases, Tropical Medicine, HIV Prevention, Public Health, and Global Health issues
Results of the WHO SOLIDARITY trial:
30 countries & 11,266 adults with #COVID19 randomized to Remdesivir, Hydroxychloroquine, Lopinavir, Interferon or no study drug.
None of these regimens had any real benefit on mortality or length of hospital stay.
Carlos Arturo Álvarez Moreno
Thu Oct 15
Primeros resultados del estudio Solidaridad. El primer análisis con 11.000 pacientes. Infortunadamente ninguno de los medicamentos probados mostró impacto en mortalidad
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results medrxiv.org/content/10.110…
#COVID__19 L'argument des fanas de l'#HCQ "c'est pour que Big Pharma vende le Remdesivir" tombe à l'eau : l'essai Solidarity de l'OMS montre que #HCQ, #remdesivir , #lopinavir, #ritonavir, #Interferon-β1a... aucun ne marche contre le Sars-Cov-2. medrxiv.org/content/10.110…pic.twitter.com/w5YSswwxUg
Lopinavir/Ritonavir: fiasco prévisible, annoncé, réalisé. Lire l’excellent article de Yazdanpanah PMID:16462674, en 2006 déjà. La Protease du VIH est totalement différente de celles des 2 #SARS. Lisez les articles scientifiques, ça sert à sauver des vies, de l énergie, des moyens twitter.com/HuetSylvestre/…